Patents for several brand-name drugs are expiring, allowing competition from generic drugs. For instance, the November expiration of the cholesterol drug Lipitor may cause a reduction in price from $25-40 per month to $4 per month, according to the report.
In the next two years, generic counterparts are expected to exist for six of the 10 best-selling drugs in the U.S., including Lipitor, Actos and Plavix. The generic competition for Lipitor will have the largest impact on consumers, according to the report. Lipitor is the top-selling drug of all time, having gained more than $9 billion in U.S. sales at one point.
Read the Los Angeles Times report on drug savings.
Related Articles on Supply Chain:
Drug Shortage, Huge Markups Angering Hospital Pharmacists
U.S. Spending on Prescription Drugs Slowed in 2010
South Dakota Hospitals Search for Ways to Weather Drug Shortage
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
